The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s demonstrating significant efficacy in clinical trials for treating obesity. Unlike some current weight loss solutions, retatrutide appears to deliver a greater substantial d